Sage Journals: Discover world-class research

Abstract

Get full access to this article

View all access options for this article.

References

1. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year results of 2 randomized clinical trials—TAP report 2. Arch Ophthalmol 2001;119:198–207.

2. Naranjo

Busto

Sellers

Sandor

Ruiz

Roberts

A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–45.

3. Messmer

Abel

SR.

Verteporfin for age-related macular degeneration. Ann Pharmacother 2001;35:1593–8. DOI 10.1345/aph.10365.

4. Noffke

Jampol

Weinberg

Munana

A potentially life-threatening adverse reaction to verteporfin (letter). Arch Ophthalmol 2001;119:143.

5. Cahill

Smith

Fekrat

Adverse reaction characterized by chest pain, shortness of breath, and syncope associated with verteporfin (Visu-dyne). Am J Ophthalmol 2002;134:281–2.

Verteporfin and myocardial infarction

Abstract

Get full access to this article

References